Details for Patent: 7,598,279
✉ Email this page to a colleague
Which drugs does patent 7,598,279 protect, and when does it expire?
Patent 7,598,279 protects XCOPRI and is included in one NDA.
This patent has twenty-four patent family members in twenty countries.
Summary for Patent: 7,598,279
Title: | Neurotherapeutic azole compounds |
Abstract: | Azole compounds containing carbamoyl group and pharmaceutically useful salts thereof are described. The compounds are effective anticonvulsants which are used in the treatment of disorders of the central nervous system, especially as anxiety, depression, convulsion, epilepsy, migraine, bipolar disorder, drug abuse, smoking, ADHD, obesity, sleep disorder, neuropathic pain, stroke, cognitive impairment, neurodegeneration, stroke and muscle spasm. |
Inventor(s): | Choi; Yong Moon (Pinebrook, NJ), Kim; Choon-Gil (Daejon, KR), Yi; Han-Ju (Daejeon, KR), Kang; Young-Sun (Daejeon, KR), Lee; Hyun-Seok (Daejeon, KR) |
Assignee: | SK Holdings Co., Ltd. (Seoul, KR) |
Application Number: | 11/407,526 |
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 7,598,279
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sk Life | XCOPRI | cenobamate | TABLET;ORAL | 212839-001 | Mar 10, 2020 | RX | Yes | Yes | 7,598,279 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
Sk Life | XCOPRI | cenobamate | TABLET;ORAL | 212839-002 | Mar 10, 2020 | RX | Yes | No | 7,598,279 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
Sk Life | XCOPRI | cenobamate | TABLET;ORAL | 212839-003 | Mar 10, 2020 | RX | Yes | No | 7,598,279 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
Sk Life | XCOPRI | cenobamate | TABLET;ORAL | 212839-004 | Mar 10, 2020 | RX | Yes | No | 7,598,279 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
Sk Life | XCOPRI | cenobamate | TABLET;ORAL | 212839-005 | Mar 10, 2020 | RX | Yes | No | 7,598,279 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
Sk Life | XCOPRI | cenobamate | TABLET;ORAL | 212839-006 | Mar 10, 2020 | RX | Yes | No | 7,598,279 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,598,279
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 1879873 | ⤷ Subscribe | 301106 | Netherlands | ⤷ Subscribe |
European Patent Office | 1879873 | ⤷ Subscribe | 122021000027 | Germany | ⤷ Subscribe |
European Patent Office | 1879873 | ⤷ Subscribe | CA 2021 00015 | Denmark | ⤷ Subscribe |
European Patent Office | 1879873 | ⤷ Subscribe | 2021C/524 | Belgium | ⤷ Subscribe |
European Patent Office | 1879873 | ⤷ Subscribe | 19/2021 | Austria | ⤷ Subscribe |
European Patent Office | 1879873 | ⤷ Subscribe | C202130027 | Spain | ⤷ Subscribe |
European Patent Office | 1879873 | ⤷ Subscribe | 132021000000101 | Italy | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |